Anika Therapeutics, Inc.
ANIK
Rank in Stocks
#16958
Anika Therapeutics, Inc. is a company dedicated to joint preservation,... Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Share Price
$13.95
Last synced: 2026-11-11
Market Cap
$186.76M
Change (1 day)
3.56%
Change (1 year)
38.12%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Anika Therapeutics, Inc. (ANIK)
Category
Healthcare
EPS for Anika Therapeutics, Inc. (ANIK)
EPS as of September 2026 TTM: $-0.13
According to Anika Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.13. At the end of 2025 the company had an EPS of $-0.76, an increase over its 2024 EPS of $-3.83.
EPS history for Anika Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.13 | -82.89% |
| 2025 | $-0.76 | -80.16% |
| 2024 | $-3.83 | -32.09% |
| 2023 | $-5.64 | 452.94% |
| 2022 | $-1.02 | -451.72% |
| 2021 | $0.29 | -117.16% |
| 2020 | $-1.69 | -187.56% |
| 2019 | $1.93 | 48.46% |
| 2018 | $1.30 | -40.37% |
| 2017 | $2.18 | -1.80% |
| 2016 | $2.22 | 7.77% |
| 2015 | $2.06 | -21.07% |
| 2014 | $2.61 | 78.77% |
| 2013 | $1.46 | 64.04% |
| 2012 | $0.89 | 36.92% |
| 2011 | $0.65 | 91.18% |
| 2010 | $0.34 | 6.25% |
| 2009 | $0.32 | 0.00% |
| 2008 | $0.32 | -41.82% |
| 2007 | $0.55 | 27.91% |
| 2006 | $0.43 | -24.56% |
| 2005 | $0.57 | -41.84% |
| 2004 | $0.98 | 1,125.00% |
| 2003 | $0.08 | -125.81% |
| 2002 | $-0.31 | -54.41% |
| 2001 | $-0.68 | -3,985.71% |
| 2000 | $0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -2,176.92% |
US
|
|
| $4.09 | -3,246.15% |
IE
|
|
| $9.45 | -7,369.23% |
US
|
|
| $2.37 | -1,923.08% |
US
|
|
| $1.77 | -1,461.54% |
US
|
Questions about Anika Therapeutics, Inc.'s earnings per share (EPS)
What is Anika Therapeutics, Inc.'s earnings per share (EPS)?
Anika Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.13, as of Sep 2026.
What was Anika Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Anika Therapeutics, Inc.'s earnings per share (EPS) was $-0.76, compared with $-3.83 in 2024.
How has Anika Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Anika Therapeutics, Inc.'s earnings per share (EPS) was highest in 2021 ($0.29) and lowest in 2023 ($-5.64).
How does Anika Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Anika Therapeutics, Inc.'s earnings per share (EPS) ($-0.13) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.